Baclofen-loaded solid lipid nanoparticles: Preparation, electrophysiological assessment of efficacy, pharmacokinetic and tissue distribution in rats after intraperitoneal administration

Lorenzo Priano, Gian Paolo Zara, Nadia El-Assawy, Stefania Cattaldo, Elisabetta Muntoni, Eva Milano, Loredana Serpe, Claudia Musicanti, Chantal Pérot, Maria Rosa Gasco, Giacinta Miscio, Alessandro Mauro

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Intrathecal baclofen administration is the reference treatment for spasticity of spinal or cerebral origin, but the risk of infection or catheter dysfunctions are important limits. To explore the possibility of alternative administration routes, we studied a new preparation comprising solid lipid nanoparticles (SLN) incorporating baclofen (baclofen-SLN). We used SLN because they are able to give a sustained release and to target the CNS. Wistar rats were injected intraperitoneally with baclofen-SLN or baclofen solution (baclofen-sol group) at increasing dosages. At different times up to 4 h, efficacy was tested by the H-reflex and two scales evaluating sedation and motor symptoms due to spinal lesions. Rats were killed and baclofen concentration determined in blood and tissues. Physiological solution or unloaded SLN was used as controls. After baclofen-SLN injection, the effect, consisting in a greater and earlier reduction of the H/M ratio than baclofen-sol group and controls, was statistically significant from a dose of 5 mg/kg and was inversely correlated with dose. Clinical effect of baclofen-SLN on both the behavioral scales was greater than that of baclofen-sol and lasted until 4th hour. Compared with baclofen-sol, baclofen-SLN produced significantly higher drug concentrations in plasma from 2nd hour until 4th hour with a linear decrement and in the brain at all times. In conclusion, our study demonstrated the efficacy of a novel formulation of baclofen, which exploits the advantages of SLN preparations. However, for clinical purposes, high baclofen concentrations in brain tissue and sedation may be unwanted effects, requiring further studies and optimization of dosages.

Original languageEnglish
Pages (from-to)135-141
Number of pages7
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume79
Issue number1
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Baclofen
Tissue Distribution
Nanoparticles
Pharmacokinetics
Lipids
Polymethyl Methacrylate
H-Reflex
Brain

Keywords

  • Baclofen
  • H-reflex
  • Intraperitoneal
  • Rats
  • Solid lipid nanoparticles
  • Spasticity

ASJC Scopus subject areas

  • Biotechnology
  • Pharmaceutical Science

Cite this

Baclofen-loaded solid lipid nanoparticles : Preparation, electrophysiological assessment of efficacy, pharmacokinetic and tissue distribution in rats after intraperitoneal administration. / Priano, Lorenzo; Zara, Gian Paolo; El-Assawy, Nadia; Cattaldo, Stefania; Muntoni, Elisabetta; Milano, Eva; Serpe, Loredana; Musicanti, Claudia; Pérot, Chantal; Gasco, Maria Rosa; Miscio, Giacinta; Mauro, Alessandro.

In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 79, No. 1, 09.2011, p. 135-141.

Research output: Contribution to journalArticle

Priano, Lorenzo ; Zara, Gian Paolo ; El-Assawy, Nadia ; Cattaldo, Stefania ; Muntoni, Elisabetta ; Milano, Eva ; Serpe, Loredana ; Musicanti, Claudia ; Pérot, Chantal ; Gasco, Maria Rosa ; Miscio, Giacinta ; Mauro, Alessandro. / Baclofen-loaded solid lipid nanoparticles : Preparation, electrophysiological assessment of efficacy, pharmacokinetic and tissue distribution in rats after intraperitoneal administration. In: European Journal of Pharmaceutics and Biopharmaceutics. 2011 ; Vol. 79, No. 1. pp. 135-141.
@article{f90ff2ed1be447e38c7b5f2afa5bcd9d,
title = "Baclofen-loaded solid lipid nanoparticles: Preparation, electrophysiological assessment of efficacy, pharmacokinetic and tissue distribution in rats after intraperitoneal administration",
abstract = "Intrathecal baclofen administration is the reference treatment for spasticity of spinal or cerebral origin, but the risk of infection or catheter dysfunctions are important limits. To explore the possibility of alternative administration routes, we studied a new preparation comprising solid lipid nanoparticles (SLN) incorporating baclofen (baclofen-SLN). We used SLN because they are able to give a sustained release and to target the CNS. Wistar rats were injected intraperitoneally with baclofen-SLN or baclofen solution (baclofen-sol group) at increasing dosages. At different times up to 4 h, efficacy was tested by the H-reflex and two scales evaluating sedation and motor symptoms due to spinal lesions. Rats were killed and baclofen concentration determined in blood and tissues. Physiological solution or unloaded SLN was used as controls. After baclofen-SLN injection, the effect, consisting in a greater and earlier reduction of the H/M ratio than baclofen-sol group and controls, was statistically significant from a dose of 5 mg/kg and was inversely correlated with dose. Clinical effect of baclofen-SLN on both the behavioral scales was greater than that of baclofen-sol and lasted until 4th hour. Compared with baclofen-sol, baclofen-SLN produced significantly higher drug concentrations in plasma from 2nd hour until 4th hour with a linear decrement and in the brain at all times. In conclusion, our study demonstrated the efficacy of a novel formulation of baclofen, which exploits the advantages of SLN preparations. However, for clinical purposes, high baclofen concentrations in brain tissue and sedation may be unwanted effects, requiring further studies and optimization of dosages.",
keywords = "Baclofen, H-reflex, Intraperitoneal, Rats, Solid lipid nanoparticles, Spasticity",
author = "Lorenzo Priano and Zara, {Gian Paolo} and Nadia El-Assawy and Stefania Cattaldo and Elisabetta Muntoni and Eva Milano and Loredana Serpe and Claudia Musicanti and Chantal P{\'e}rot and Gasco, {Maria Rosa} and Giacinta Miscio and Alessandro Mauro",
year = "2011",
month = "9",
doi = "10.1016/j.ejpb.2011.02.009",
language = "English",
volume = "79",
pages = "135--141",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Baclofen-loaded solid lipid nanoparticles

T2 - Preparation, electrophysiological assessment of efficacy, pharmacokinetic and tissue distribution in rats after intraperitoneal administration

AU - Priano, Lorenzo

AU - Zara, Gian Paolo

AU - El-Assawy, Nadia

AU - Cattaldo, Stefania

AU - Muntoni, Elisabetta

AU - Milano, Eva

AU - Serpe, Loredana

AU - Musicanti, Claudia

AU - Pérot, Chantal

AU - Gasco, Maria Rosa

AU - Miscio, Giacinta

AU - Mauro, Alessandro

PY - 2011/9

Y1 - 2011/9

N2 - Intrathecal baclofen administration is the reference treatment for spasticity of spinal or cerebral origin, but the risk of infection or catheter dysfunctions are important limits. To explore the possibility of alternative administration routes, we studied a new preparation comprising solid lipid nanoparticles (SLN) incorporating baclofen (baclofen-SLN). We used SLN because they are able to give a sustained release and to target the CNS. Wistar rats were injected intraperitoneally with baclofen-SLN or baclofen solution (baclofen-sol group) at increasing dosages. At different times up to 4 h, efficacy was tested by the H-reflex and two scales evaluating sedation and motor symptoms due to spinal lesions. Rats were killed and baclofen concentration determined in blood and tissues. Physiological solution or unloaded SLN was used as controls. After baclofen-SLN injection, the effect, consisting in a greater and earlier reduction of the H/M ratio than baclofen-sol group and controls, was statistically significant from a dose of 5 mg/kg and was inversely correlated with dose. Clinical effect of baclofen-SLN on both the behavioral scales was greater than that of baclofen-sol and lasted until 4th hour. Compared with baclofen-sol, baclofen-SLN produced significantly higher drug concentrations in plasma from 2nd hour until 4th hour with a linear decrement and in the brain at all times. In conclusion, our study demonstrated the efficacy of a novel formulation of baclofen, which exploits the advantages of SLN preparations. However, for clinical purposes, high baclofen concentrations in brain tissue and sedation may be unwanted effects, requiring further studies and optimization of dosages.

AB - Intrathecal baclofen administration is the reference treatment for spasticity of spinal or cerebral origin, but the risk of infection or catheter dysfunctions are important limits. To explore the possibility of alternative administration routes, we studied a new preparation comprising solid lipid nanoparticles (SLN) incorporating baclofen (baclofen-SLN). We used SLN because they are able to give a sustained release and to target the CNS. Wistar rats were injected intraperitoneally with baclofen-SLN or baclofen solution (baclofen-sol group) at increasing dosages. At different times up to 4 h, efficacy was tested by the H-reflex and two scales evaluating sedation and motor symptoms due to spinal lesions. Rats were killed and baclofen concentration determined in blood and tissues. Physiological solution or unloaded SLN was used as controls. After baclofen-SLN injection, the effect, consisting in a greater and earlier reduction of the H/M ratio than baclofen-sol group and controls, was statistically significant from a dose of 5 mg/kg and was inversely correlated with dose. Clinical effect of baclofen-SLN on both the behavioral scales was greater than that of baclofen-sol and lasted until 4th hour. Compared with baclofen-sol, baclofen-SLN produced significantly higher drug concentrations in plasma from 2nd hour until 4th hour with a linear decrement and in the brain at all times. In conclusion, our study demonstrated the efficacy of a novel formulation of baclofen, which exploits the advantages of SLN preparations. However, for clinical purposes, high baclofen concentrations in brain tissue and sedation may be unwanted effects, requiring further studies and optimization of dosages.

KW - Baclofen

KW - H-reflex

KW - Intraperitoneal

KW - Rats

KW - Solid lipid nanoparticles

KW - Spasticity

UR - http://www.scopus.com/inward/record.url?scp=80052261944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052261944&partnerID=8YFLogxK

U2 - 10.1016/j.ejpb.2011.02.009

DO - 10.1016/j.ejpb.2011.02.009

M3 - Article

C2 - 21352914

AN - SCOPUS:80052261944

VL - 79

SP - 135

EP - 141

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

IS - 1

ER -